These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
49. Varicella vaccination in Australia and New Zealand. Macartney KK; Burgess MA J Infect Dis; 2008 Mar; 197 Suppl 2():S191-5. PubMed ID: 18419396 [TBL] [Abstract][Full Text] [Related]
50. Chickenpox vaccines: new drugs. A favourable risk-benefit balance in some situations. Prescrire Int; 2005 Jun; 14(77):85-91. PubMed ID: 15977369 [TBL] [Abstract][Full Text] [Related]
51. The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom. van Hoek AJ; Melegaro A; Gay N; Bilcke J; Edmunds WJ Vaccine; 2012 Feb; 30(6):1225-34. PubMed ID: 22119592 [TBL] [Abstract][Full Text] [Related]
52. Varicella vaccination of children in the United States: assessment after the first decade 1995-2005. Grose C J Clin Virol; 2005 Jun; 33(2):89-95; discussion 96-8. PubMed ID: 15911422 [TBL] [Abstract][Full Text] [Related]
54. Herpes zoster-related hospitalizations and expenditures before and after introduction of the varicella vaccine in the United States. Patel MS; Gebremariam A; Davis MM Infect Control Hosp Epidemiol; 2008 Dec; 29(12):1157-63. PubMed ID: 18999945 [TBL] [Abstract][Full Text] [Related]
55. Varicella-zoster virus disease and epidemiology: seeking better control strategies--Part 1. Bentsi-Enchill A Can Commun Dis Rep; 1998 Dec; 24(24):193-8. PubMed ID: 9916347 [No Abstract] [Full Text] [Related]
56. Varicella outbreak epidemiology in an active surveillance site, 1995-2005. Civen R; Lopez AS; Zhang J; Garcia-Herrera J; Schmid DS; Chaves SS; Mascola L J Infect Dis; 2008 Mar; 197 Suppl 2():S114-9. PubMed ID: 18419383 [TBL] [Abstract][Full Text] [Related]
57. Safety of varicella vaccine after licensure in the United States: experience from reports to the vaccine adverse event reporting system, 1995-2005. Chaves SS; Haber P; Walton K; Wise RP; Izurieta HS; Schmid DS; Seward JF J Infect Dis; 2008 Mar; 197 Suppl 2():S170-7. PubMed ID: 18419393 [TBL] [Abstract][Full Text] [Related]
59. Analysis of the cost-effectiveness of varicella vaccine programmes based on an observational survey in the Latium region of Italy. Gialloreti LE; Divizia M; Pica F; Volpi A Herpes; 2005 Oct; 12(2):33-7. PubMed ID: 16209858 [TBL] [Abstract][Full Text] [Related]
60. The incidence of varicella and herpes zoster in Taiwan during a period of increasing varicella vaccine coverage, 2000-2008. Chao DY; Chien YZ; Yeh YP; Hsu PS; Lian IB Epidemiol Infect; 2012 Jun; 140(6):1131-40. PubMed ID: 21906410 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]